Advertisement

Prophylactic treatment of renal stone disease with magnesium hydroxide during five years

  • G. Johansson
  • U. Backman
  • B. G. Danielson
  • B. Fellström
  • S. Ljunghall
  • B. Wikström
Conference paper
Part of the Fortschritte der Urologie und Nephrologie book series (2824, volume 20)

Abstract

Already in the year 1810 (Brande) was magnesium proposed as prophylactic treatment against renal stone disease. It was later shown that magnesium increased the solubility of calcium oxalate in vitro (Hammarsten, 1929). Desmars and Tawashi (1973) demonstrated the greater solubility product for magnesium oxalate than for calcium oxalate and magnesium has also been found to account for 20% of the total inhibitory activity of calcium phosphate precipitation in whole urine (Bisaz et al., 1978).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    de Albuquerque, P. F., Tuma, M.: Investigations on urolithiasis. II: Studies on oxalate. J. Urol. 87: 504 (1962).Google Scholar
  2. 2.
    Bisaz, S., Felix, R., Neumann, W. F., Fleisch, H.: Quantitative determination of inhibitors of calcium phosphate precipitation in whole urine. Mineral Electrolyte Metab. 1: 74 (1978).Google Scholar
  3. 3.
    Brande, W. T.; Observations on the effects of magnesia in preventing an increased formation of uric acid; with some remarks on the composition of urine. Med. Phys. J. 24: 203 (1810).Google Scholar
  4. 4.
    Danielson, B. G., Johansson, G., Ljunghall, S.: Magnesium metabolism in healthy subjects. Scand. J. Urol. Nephrol. 51 (suppl): 49 (1979).Google Scholar
  5. 5.
    Desmars, J. F., Tawashi, R.: Dissolution and growth of calcium oxalate monohydrate. I. Effect of magnesium and pH. Biochim. Biophys. Acta 313: 256 (1973).PubMedCrossRefGoogle Scholar
  6. 6.
    Gershoff, S. N., Prien, E. L.: Effect of daily MgO and vitamin B6 administration to patients with recurring calcium oxalate kidney stones. Am. J. Clin. Nutr. 20: 393 (1967).PubMedGoogle Scholar
  7. 7.
    Hammarsten, G.: On calcium oxalate and its solubility in the presence of inorganic salts with special reference to the occurrence of oxaluria. C R Lab. Carlsberg 17: 1 (1929).Google Scholar
  8. 8.
    Johansson, G., Backman, U., Danielson, B. G., Ljunghall, S., Wikström, B.: Magnesium metabolism in renal stone disease. Invest. Urol. 18: 93 (1980a).PubMedGoogle Scholar
  9. 9.
    Johansson, G., Backmann, U., Danielson, B. G., Fellström, B., Ljunghall, S., Wikström, B.: Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide. J. Urol. 124: 770 (1980b).PubMedGoogle Scholar
  10. 10.
    Johansson, G., Backman, U., Danielson, B. G., Fellström, B., Ljunghall, S., Wikström, B.: Prophylactic treatment with magnesium hydroxide in renal stone disease. In: Urolithiasis: Clinical and basic research. (Ed. L. H. Smith ), pp 267–274. Plenum Publishing Corporation, 1981.Google Scholar
  11. 11.
    Wikström, B., Backman, U., Danielson, B. G., Fellström, B., Johansson, G., Ljunghall, S.: Urinary citrate excretion and acidification defects in renal calcium stone formers. In: Urolithiasis: Clinical and basic research. (Ed. L. H. Smith ), pp 757–762. Plenum Publishing Corporation, New York, 1981.Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1982

Authors and Affiliations

  • G. Johansson
    • 1
  • U. Backman
    • 1
  • B. G. Danielson
    • 1
  • B. Fellström
    • 1
  • S. Ljunghall
    • 1
  • B. Wikström
    • 1
  1. 1.Department of Internal MedicineUniversity HospitalUppsalaSchweden

Personalised recommendations